Stem Cell Treatment for Rheumatoid Arthritis Cost in Tijuana, Mexico

In 2026, RA stem cell therapy in Tijuana costs $5,000-$15,000. This is 50-70% less than US prices, which often exceed $30,000 for comparable mesenchymal cell protocols.

Lower operational costs and regulatory differences in Mexico allow for affordable pricing. Patients receive high-quality care at a fraction of the cost found in US or Canadian clinics.

Clinics typically use umbilical cord-derived mesenchymal stem cells (UC-MSCs). These cells are effective at reducing inflammation and regulating the overactive immune system in RA patients.

Yes, provided the facility is COFEPRIS-certified. Mexico follows strict federal guidelines to ensure the safety, sterility, and ethical sourcing of all cellular tissue used.

A 3 to 5-day trip is recommended. This window covers the initial physical assessment, the infusion procedure, and necessary follow-up monitoring before you return home safely.

Results are not typically permanent but can last 1 to 2 years. Many patients schedule periodic follow-up treatments to maintain the anti-inflammatory effects and joint mobility benefits.

Most major insurance providers do not cover stem cell therapy as it is categorized as an elective procedure. Patients usually utilize private savings or specialized medical financing.

Many patients report significant improvements in pain and mobility. Clinical focus remains on modulating the immune system to slow disease progression and joint damage.

Treatment is mostly delivered via IV infusion for systemic immune modulation. Doctors may also perform localized joint injections to target areas with severe inflammation or pain.

International patients need a valid passport to enter Mexico. Tijuana’s proximity to the San Diego border makes it a highly accessible destination for North American patients.

It is often a complementary treatment. While some patients reduce reliance on biologics, any changes to medication should only be made under professional medical guidance.

Candidates typically include those with moderate to severe RA who haven't responded to traditional meds. A medical review of your history is required to determine eligibility.